Future studies are needed to better understand this association, says Jonathan Zontag , lead study author and a researcher at Hebrew University
Recent Findings Preliminary data suggest that GLP-1 RA can modulate crucial pathways in the pathogenesis of IBD, such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity
Some users may notice improvements in appetite control and digestion within weeks, while others may take longer to experience changes
Cuomo notes that while these results are observational, they underscore an urgent need for clinical trials to test whether GLP-1 drugs can improve cancer survival rates, especially for patients with obesity-related cancers
Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus
Oprah stepped down from WeightWatchers board in early 2024, just as the company began reinventing itself for the modern era of weight loss